We have read this research and we think that is very important so we have made a research about the diabetic foot which is a serious health problem in Cuba and the world. Injuries resulting from this condition lead to mutilation of these patients by amputations. Cuba is keen to try to heal diabetic foot lesions. 15% of diabetics have these ulcers at some point in their lives. In Cuba in a study in hospitals in Havana in 2007 reported that 29% of patients discharged with a diagnosis of diabetic foot underwent a major amputation of one of his legs with a mortality of 10.2%.

Various treatments have been used in various diabetic foot injuries, preventive, medical and surgical, but still have not managed to reduce this cause mutilation, especially in grade IV ulcers WagnerÇ classification.

In the city of Trinidad, Cuba, a study in 31 diabetic patients undergoing treatment with Heberprot-P from January 2011 to May 2012 with the aim to analyze and elaborate the results obtained. After application of a comprehensive model of diabetic foot care, there is a significant decrease in mortality indicators after the implementation of the program of diabetes care. Cuba now has an elite product, unique in its type. This product is an epidermal growth factor (EGF). FCE is a polypeptide of 53 amino acids and 6 Kd.1954: Obtained at the Center for Genetic Engineering and Biomolecular (IGBC) in Cuba and by recombinant DNA technology, to insert the human gene in Saccharomyces cerevisiae EGF. Heberprot-P is a formulation of the human epidermal growth factor recombinant drug. Accelerates the healing of diabetic foot ulcers (UPD) deep and complex, reduces the risk of amputations in patients with UPD and contributes significantly to improving the quality of life of patients. Among the key findings is that 58.6% were between 50-59 years of age and over 50% of the patients belonged to the female gender.

Competing interests: None declared